## PFE: Pfizer, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.8% below STRENGTH zone (3.0-6.0%); PEG 3.77 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.3% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($23.97)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Pfizer (NYSE: PFE) CEO reports 23 Phantom Stock Units, holds 743,115**
- Source: Stock Titan | 20251202T173200 | Neutral | Relevance: 99%
- Pfizer Inc. Chairman and CEO Albert Bourla reported acquiring 23 Phantom Stock Units on November 28, 2025, each representing one phantom share of Pfizer common stock at a reference price of $25.74. Following this transaction, Bourla beneficially owns a total of 743,115 phantom stock units. These units are part of Pfizer's Nonfunded Deferred Compensation and Supplemental Savings Plan, settled in cash upon separation from service, and can be moved to an alternative investment account by Bourla at any time.

**2. Pfizer's Cancer Drugs Deliver Growth Amid Competitive Pressure**
- Source: www.sharewise.com | 20251202T162400 | Bullish | Relevance: 99%
- Pfizer is experiencing growth in its oncology division, driven by a strong portfolio of cancer medicines and the strategic acquisition of Seagen. Despite competitive pressures and declining sales for some older drugs like Ibrance, newer therapies and a robust pipeline are contributing to increased revenues. The company expects to have eight or more blockbuster oncology medicines by 2030, reinforcing oncology as a central driver for its long-term outlook, even as its stock performance lags the industry.

**3. Pfizer Inc. (PFE) stock price, news, quote and history**
- Source: Yahoo Finance Singapore | 20251202T005140 | Neutral | Relevance: 98%
- This article provides a comprehensive overview of Pfizer Inc. (PFE) stock, including its current price, historical data, and key financial metrics. It details the company's product offerings, therapeutic areas, and collaboration agreements, alongside performance over various periods and analyst insights. The page also features earnings trends, valuation measures, and tools to compare Pfizer with similar pharmaceutical companies.

**4. Pfizer (PFE) Valuation in Focus After FDA Approves PADCEV Combo for Bladder Cancer**
- Source: Simply Wall Street | 20251130T233026 | Bullish | Relevance: 98%
- Pfizer's valuation is under scrutiny following FDA approval of its PADCEV combination with pembrolizumab for bladder cancer, enhancing its oncology pipeline and revenue potential. Despite a robust 1-year total shareholder return of 5.3%, the stock is still recovering from a challenging three-year period, with its fair value estimated at $29.08, suggesting it is currently undervalued. This optimistic outlook is based on strong margin assumptions and future earnings, but potential regulatory and competitive challenges could impact future performance.

**5. Pfizer Partner 3SBio To Raise $400 Million In Stock Sale**
- Source: Forbes | 20251202T234800 | Bullish | Relevance: 98%
- 3SBio, a Chinese partner of Pfizer, plans to raise approximately $400 million through a share placement, primarily for research and development. This follows a previous agreement in July where Pfizer invested $100 million in 3SBio, aiming to advance cancer medicines. The collaboration highlights continued U.S.-China ties in healthcare despite broader trade tensions, with 3SBio's shares soaring over 300% in the past year.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-24 | Guggenheim | $35 | $33 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-24 | Guggenheim | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 12 ($0.22M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 31.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.4% (+0.2%)
- Blackrock Inc.: 8.8% (+0.5%)
- State Street Corpora: 5.3% (+0.9%)
- Geode Capital Manage: 2.3% (+1.2%)
- Morgan Stanley: 1.3% (+6.6%)

### Key Risks

1. Valuation stretched: PEG 3.8x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.77 signals overvaluation risk, limited margin of safety. Quality metrics strong (margin 16%). Balance sheet: $4.0B free cash flow. Analyst sentiment positive (1 raises, avg +6%). Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $146.6B |
| Beta | 0.42 |
| 52W Range | $20.92 - $27.69 |
| Short Interest | 2.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.77 |
| Forward P/E | 8.1 |
| Current P/E | 8.0 |
| YoY Growth | -1.6% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 0.5% to -2.8% (-3.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.8pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 50.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.84% (CS: 24) | Weak |
| RSI_14 | 50.5 | Neutral |
| MACD Histogram | 0.02 | Bullish |
| vs SMA20 | 1.001x | Above |
| vs SMA50 | 1.005x | Above |
| vs SMA200 | 1.024x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $25.15
- **Stop Loss:** $23.97 (4.7% risk)
- **Target:** $26.33 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 847
- **Position Value:** $21,302.05
- **Portfolio %:** 21.30%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-03 (Est: $0.60)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.63 | $0.87 | +37.4% |
| 2025Q2 | $0.57 | $0.78 | +35.9% |
| 2025Q1 | $0.67 | $0.92 | +36.5% |
| 2024Q4 | $0.46 | $0.63 | +37.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*